Fortune Talks Up Genentech
Published on June 7, 2003
After catching up with my reading list this weekend, I have to point you to a few articles of interest: First, David Stipp visits Genentech and reviews why their stock has really taken off (nothing new for the informed medchemist) and why their CEO is not focused on producing blockbuster drugs (yeah, right). The author makes the point that Genentech has deliberately not become like everyone else in big pharma — I guess it’s easy to make a virtue out of it if your company just didn’t have the revenues to do anything but staying small and lean. Read how Genentech Got It …